6:00 PM
Apr 21, 2008
 |  BC Extra  |  Company News

EC approves Celgene's thalidomide

The European Commission approved an MAA for Thalidomide Pharmion from Celgene (NASDAQ:CELG) to treat newly diagnosed multiple myeloma (MM) in combination with melphalan...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >